We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $143M
1-Year Est. Return 773.18%
This Fund
S&P 500
This Quarter Est. Return
+42.28%
1 Year Est. Return
+773.18%
3 Year Est. Return
+7,269.42%
5 Year Est. Return
+14,284.66%
10 Year Est. Return
+1,769,765.59%
AUM
$142M
AUM Growth
-$5.53M
Cap. Flow
-$27M
Cap. Flow %
-19.05%
Top 10 Hldgs %
77.36%
Holding
36
New
6
Increased
6
Reduced
13
Closed
9

Top Buys

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$4.19M
2
STRO icon
Sutro Biopharma
STRO
+$3.65M
3
DRUG
Bright Minds Biosciences
DRUG
+$2.22M
4
TNGX icon
Tango Therapeutics
TNGX
+$2.21M
5
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$2.19M

Top Sells

Rank Stock Value
1
CDTX
Cidara Therapeutics
CDTX
+$19.7M
2
TERN
Terns Pharmaceuticals
TERN
+$5.8M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$4.93M
4
INSM icon
Insmed
INSM
+$4.5M
5
OCUL icon
Ocular Therapeutix
OCUL
+$4.39M

Sector Composition

Rank Sector Weight
1 Healthcare 97.59%
2 Miscellaneous 2.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNCY icon
26
Unicycive Therapeutics
UNCY
$147M
$381K 0.27%
57,959
-2,026
-3% -$13.3K
CDTX
27
DELISTED
Cidara Therapeutics
CDTX
– –
-89,145
Closed -$19.7M
DNTH icon
28
Dianthus Therapeutics
DNTH
$5.92B
– –
-16,708
Closed -$689K
INBX icon
29
Inhibrx
INBX
$1.82B
– –
-16,377
Closed -$1.29M
INSM icon
30
Insmed
INSM
$25.9B
– –
-25,878
Closed -$4.5M
JAZZ icon
31
Jazz Pharmaceuticals
JAZZ
$15.9B
– –
-29,008
Closed -$4.93M
KTTA icon
32
Pasithea Therapeutics
KTTA
$18.7M
– –
-450,000
Closed -$581K
NUVB.WS
33
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
– –
-90,832
Closed -$30K
VSTM icon
34
Verastem
VSTM
$654M
– –
-143,446
Closed -$1.11M
ZYME icon
35
Zymeworks
ZYME
$2.02B
– –
-80,143
Closed -$2.11M
1
2

Similar funds

FPC
Flax Pond Capital Falmouth, Massachusetts $143M AUM
WWM
Woodside Wealth Management Framingham, Massachusetts $144M AUM 22.2% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
BOM
Bank of Marin Novato, California $143M AUM 26.89% 1-Year Est. Return
PWM
Pathway Wealth Management Dallas, Texas $143M AUM
FF
Fox Financial Wyomissing, Pennsylvania $144M AUM 28.05% 1-Year Est. Return
JPT
Jordan Park Trust Portsmouth, New Hampshire $143M AUM 15.59% 1-Year Est. Return
BJF
Blue Jean Financial Albany, New York $144M AUM

Acuta Capital Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Acuta Capital Partners held 36 positions worth $142M, down 3.8% from $147M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Acuta Capital Partners withdrew a net $27M in Q1 2026, closing 9 positions and reducing 13 holdings. Its most notable exit was Cidara Therapeutics, an estimated $19.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Acuta Capital Partners opened a new position in Erasca worth $5.74M.

  • Acuta Capital Partners's largest Q1 2026 buy was Erasca: 354,575 shares worth $5.74M.
  • Acuta Capital Partners added most to Sutro Biopharma in Q1 2026, an estimated $3.65M increase.
  • Acuta Capital Partners's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $5.8M.
  • Acuta Capital Partners fully exited Cidara Therapeutics in Q1 2026, selling an estimated $19.7M.
  • Acuta Capital Partners's ten largest holdings make up 77% of its $142M portfolio in Q1 2026.
  • Acuta Capital Partners opened 6 new positions and closed 9 in Q1 2026.
  • Acuta Capital Partners's portfolio value fell 3.8% quarter-over-quarter to $142M.

Based on Acuta Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.